Why This Matters
One of the most persistent challenges in Alzheimer's disease is that two patients can receive the same medication and experience completely different outcomes. Doctors prescribing drugs to manage the psychiatric symptoms of Alzheimer's, such as depression, anxiety, and agitation, have few reliable ways to predict in advance who will respond and who will not. Most patients go through extended trial-and-error sequences before finding a medication that helps.
Researchers at Johns Hopkins Medicine have developed a laboratory model that may eventually help solve that problem, not for every aspect of Alzheimer's disease, but for a specific and clinically important subset: predicting whether a given patient's brain tissue will respond to a particular drug.
The approach uses brain organoids, miniature clusters of living brain-like tissue grown from a patient's own stem cells. By testing medications directly on tissue derived from an individual patient before prescribing, researchers hope to identify which patients are likely to benefit from which drugs. The technology is years from clinical use, but the early results are specific enough to be clinically meaningful.
What We Know So Far
The study, led by Dr. Vasiliki Mahairaki of the Johns Hopkins School of Medicine and published in Alzheimer's & Dementia on April 8, 2026, generated the largest cohort of patient-derived brain organoids for Alzheimer's research to date: 30 independent lines derived from individuals with Alzheimer's disease and healthy controls. A ScienceDaily press release on July 22, 2026, brought the findings to broader attention.
The team generated what they call serotonergic hindbrain organoids: miniature brain-like structures containing serotonin-producing neurons, grown from induced pluripotent stem cells derived from the study participants. These organoids were then exposed to escitalopram oxalate, a commonly prescribed selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat depression and anxiety symptoms in Alzheimer's patients.
The results showed striking heterogeneity. In some patient-derived organoids, escitalopram increased levels of proteins involved in serotonin signaling and communication between brain cells. In other organoids derived from different patients, the researchers observed little to no change. The same drug produced meaningfully different effects across tissue from different individuals.
Where the Research Stands
The organoids also captured biological features of Alzheimer's disease itself. Tissue derived from patients with Alzheimer's showed reduced levels of proteins known to be important for normal brain cell signaling, including RAB3A, NSF, and ATCAY, compared to organoids from healthy controls.
The researchers also examined extracellular vesicles: tiny particles released by the organoids that carry proteins reflecting the cellular state of the tissue. These particles may eventually serve as minimally invasive biomarkers, because similar vesicles circulate in human blood and cerebrospinal fluid. If validated, measuring them could allow clinicians to assess Alzheimer's disease biology and drug response without requiring a brain biopsy.
Dr. Mahairaki explained the long-term vision for the technology: "On a large-scale level, our model may eventually be used to identify subgroups of patients, based on underlying molecular mechanisms, who are more likely to respond to certain drugs and thus help us to create precise, targeted treatments in the long run."
What Doctors and Experts Say
The study reflects a broader shift in Alzheimer's research toward recognizing that the disease is not one condition but a collection of conditions that share certain outward features while differing significantly at the molecular level. That heterogeneity has been one reason why drugs that work in clinical trials on average may fail to help many individual patients.
Johns Hopkins researchers noted that the organoids and the extracellular vesicles they release could serve dual purposes: as a platform for testing candidate drugs before prescription, and as a source of biomarkers that help clinicians understand where in the disease progression an individual patient currently sits.
One of the study participants whose cells were used to generate the organoids was additionally diagnosed with neuropsychiatric symptoms, a subset of Alzheimer's disease that includes depression, anxiety, agitation, and psychosis and affects the majority of people with Alzheimer's disease at some point during the illness.
What the Evidence Shows and What It Does Not
This research is preclinical. The organoids are not a human brain; they are a simplified model that captures some but not all features of actual neural tissue. They do not include the full complement of brain cell types, the vascular system, the immune cells, or the complex connectivity of a living brain.
The study cohort of 30 individuals, while the largest of its kind for this specific organoid model, is still a small sample from which it would be premature to draw broad clinical conclusions. The drug tested, escitalopram, was chosen because it is commonly prescribed to manage psychiatric symptoms in Alzheimer's disease, not because it has been shown to modify the course of the disease itself.
Critically, this study does not offer any information about whether escitalopram or any other SSRI improves clinical outcomes in Alzheimer's patients. It shows that different patients' brain tissue responds differently to the drug at a molecular level in a laboratory setting. Whether those molecular differences predict clinical benefit remains unknown.
MedicalDaily Evidence Check
- Study type: Preclinical laboratory study using patient-derived brain organoids
- Institution: Johns Hopkins Medicine
- Published in: Alzheimer's & Dementia (DOI: 10.1002/alz.71273), April 8, 2026; ScienceDaily press release July 22, 2026
- Participants: 30 iPSC lines derived from Alzheimer's patients and healthy controls
- What it found: Patient-derived brain organoids showed variable responses to the SSRI escitalopram, consistent with the known heterogeneity of Alzheimer's disease at the molecular level
- What it did not prove: That organoid testing predicts clinical drug response in living patients; that escitalopram improves outcomes in Alzheimer's disease; that this technology is ready for clinical use
-
What readers should know: This is basic science research with important long-term implications; clinical application is years away
Who Faces the Greatest Risk — or May Benefit Most?
Alzheimer's disease affects an estimated 7 million Americans, and its neuropsychiatric symptoms, including depression, anxiety, and behavioral changes, affect the majority of patients at some point. Those symptoms are often managed with SSRIs, antipsychotics, and other medications, frequently through trial-and-error because no reliable biomarkers exist to predict individual response.
The populations most likely to benefit from a personalized drug-testing technology, if it is eventually validated for clinical use, include:
- People with early-stage Alzheimer's disease who are beginning to manage neuropsychiatric symptoms
- Patients for whom multiple medication trials have failed, suggesting underlying biological heterogeneity
- People with Alzheimer's who are also experiencing depression or severe agitation that significantly reduces quality of life
-
Younger-onset Alzheimer's patients, who often present with more complex symptom profiles
Symptoms and Warning Signs to Watch For
The neuropsychiatric symptoms of Alzheimer's disease that are most commonly managed with antidepressants and related medications include:
- Persistent low mood or withdrawal from previously enjoyed activities
- Increased anxiety or fearfulness that interferes with daily function
- Agitation, restlessness, or verbal and physical aggression
- Sleep disturbances
- Hallucinations or delusional thinking, particularly in moderate to advanced disease
These symptoms should be assessed by a physician or specialist familiar with Alzheimer's disease management. They may also signal a worsening of the underlying disease and should be reported to the treating neurologist or geriatrician.
What You Can Do Now
- If you are a caregiver for someone with Alzheimer's who is experiencing neuropsychiatric symptoms, speak with their physician or a specialist in geriatric psychiatry about current medication options and their evidence base.
- Ask about clinical trials at Alzheimer's Association Trial Match , which connects eligible individuals with open research studies.
-
Contact the
Alzheimer's Association
at 1-800-272-3900 for guidance on managing behavioral and psychological symptoms and accessing caregiver support.
Cost and Access: What Patients Should Know
Brain organoid testing for individual drug response is not available outside of research settings and is not covered by any insurance. The technology, as it currently exists, is a laboratory tool used to understand disease biology and generate hypotheses about drug response, not a clinical diagnostic test.
For patients currently managing neuropsychiatric symptoms of Alzheimer's, escitalopram and other SSRIs are available as inexpensive generics covered by most insurance plans and Medicare Part D. Decisions about which medication to try should be made with a clinician who is familiar with both the patient's symptom profile and their overall medication regimen.
What Happens Next
The Johns Hopkins team has indicated that this dual platform approach, using both organoids and extracellular vesicles, advances what they call precision medicine by enabling scalable, patient-specific drug screening and biomarker discovery. The next phase of research would involve testing predictions from the organoid model against actual clinical outcomes in patients, a step that has not yet been completed.
Validation of the approach in a prospective clinical study would be required before it could influence prescribing decisions. That level of evidence could be a decade or more away, depending on funding, regulatory interest, and whether the technology can be made scalable enough to be practical in a clinical setting.
The Bottom Line
Researchers at Johns Hopkins Medicine have demonstrated that miniature brain models grown from Alzheimer's patients' own cells can reveal meaningful differences in how individual patients' tissue responds to the same medication. The technology is preclinical and far from clinical use, but it represents a genuine step toward understanding the biological variability that makes Alzheimer's treatment so difficult to individualize. For the 7 million Americans living with the disease and the families supporting them, research like this points toward a future in which treatment decisions could be guided by each patient's own biology rather than population averages.
